XORTX Appoints Michael Bumby As CFO, Replacing James Fairbairn

(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company, Thursday announced the appointment of biotech/pharma industry veteran Michael Bumby as Chief Financial Officer.

Bumby, who is replacing CFO James Fairbairn, is currently a director and audit committee chair of MediPharm Labs following their acquisition of VIVO Cannabis Inc. He was the CFO of VIVO for six years.

Previously, he had a 14-year career at drug major Eli Lilly.

Chairman Anthony Giovinazzo said, "His dual science-finance background and extensive business and drug development experience will help XORTX meet its near and longer-term objectives."

XRTX closed Wednesday's regular trading 4.27% higher at $1.12 on the Nasdaq.